The goal of thrombolytic treatment in acute myocardial infarction is reperfusion of the infarct-related coronary artery. Duteplase is a double-chain recombinant tissue-type plasminogen activator. Its efficacy and safety were evaluated in patients with acute myocardial infarction treated within 4 h of onset of chest pain in this multicentre, open, non-controlled trial.
Background
The goal of thrombolytic treatment in acute myocardial infarction is reperfusion of the infarct-related coronary artery. Duteplase is a double-chain recombinant tissue-type plasminogen activator. Its efficacy and safety were evaluated in patients with acute myocardial infarction treated within 4 h of onset of chest pain in this multicentre, open, non-controlled trial.
Methods and results A total of 273 patients were enrolled and treated with duteplase 0-6 MU . kg~ ' over 4 h, with concomitant oral aspirin and intravenous heparin. Coronary arteriography was performed at 60 min, 90 min and approximately 24 h after the start of duteplase infusion to assess the perfusion grade (TIMI scoring) of the infarct-related coronary artery. Safety was assessed by monitoring patients closely for bleeding and for all other adverse experiences during the 72-h study period. Reinfarction during the study period was also recorded, and deaths at any time during the period in hospital were documented.
TIMI grade 2 or 3 patency of the infarct-related coronary artery at 90 min was achieved in 70% of the patients and 7% of these 'patent' infarct-related coronary arteries had reoccluded by 20 to 36 h. Clinical reinfarction during the 72-h study period was observed in 7%. Total in-hospital mortality was 8%. Serious or life-threatening bleeding occurred in 4% of the patients. There was one haemorrhagic stroke, and this was fatal.
Introduction
In the development of new thrombolytic drugs for use in acute myocardial infarction one of the key features by which efficacy may be assessed is the patency of the infarct-related coronary artery, judged by coronary arteriographic appearances, at specified times after administration of the drug 11 ' 21 . Although the assessment of the full clinical value of a thrombolytic drug in acute myocardial infarction should include far more than establishing the achievable early patency figure for the infarct-related coronary artery, the infarct-related coronary artery patency figure has been relied upon as the only practicable technique for the initial exploratory work on dose and regimen for such drugs' 2 ' 31 . Duteplase (Wellcome Foundation) is a recombinant double-chain form of tissue-type plasminogen activator produced in deep culture by Chinese hamster ovary cells transfected with the gene for tissue-type plasminogen activator. Its amino acid sequence differs from that of wild-type tissue-type plasminogen activator by one amino acid -a substitution of methionine for valine at position 245 in an overall chain length of 527 amino acids. The activity of duteplase is expressed in megaunits of thrombolytic activity (1 MU=1 x 10 6 units of thrombolytic activity as determined by a clot lysis assay using the Second International Standard for tissue-type plasminogen activator). The specific activity of duteplase is approximately 0-31 MU per mg of protein, compared with 058 MU per mg of protein for the predominantly single-chain alteplase. One of the first clinical studies with duteplase in which patients with acute myocardial infarction were given one of three doses of the drug intravenously at a constant rate over 90 min, starting within 4 h of onset of symptoms, showed that even in the highest dose group (30-48 MU) early patency of the infarct-related coronary artery was only 53% [4) . However, other investigators studying alteplase -a predominantly single-chain recombinant tissue-type plasminogen activator -in acute myocardial infarction were reporting higher infarct-related coronary artery early patency figures using a regimen with an initial bolus, a high dose for 1 h, and then a lower dose for several more hours' 51 . There was also evidence that haemorrhagic complications become more frequent at higher doses' , and those working in the Wellcome duteplase clinical trials programme 18191 concluded that dose-by-weight regimen was likely to optimize both efficacy and safety of tissue-type plasminogen activator treatment in acute myocardial infarction. Subsequent studies with duteplase were therefore conducted dosing according to body weight and, taking account of evidence that prolonged infusions of duteplase did not prevent reocclusion after successful thrombolysis' 101 , with a stepped regimen of bolus/high dose for 1 h followed by a lower dose for 3 h. Although early patency of the infarct-related coronary artery had been the primary focus of attention in evaluating efficacy of different thrombolytic drugs and regimens in acute myocardial infarction, it was appreciated that the clinical course and subsequent prognosis would also depend on maintenance of patency '. The present study was undertaken to examine the efficacy, as judged by 60-and 90-min patency as well as by reocclusion at 24 h of the infarct-related coronary artery, and safety of a weight-adjusted regimen of duteplase in acute myocardial infarction. The duteplase regimen was that adopted for the tissue-type plasminogen activator arm of the Third International Study of Infarct Survival (ISIS-3), in which a randomized comparison of duteplase, streptokinase and anisoylated plasminogen-streptokinase activator complex was made in patients who could be entered into the study within 24 h of onset of suspected acute myocardial infarction' 131 . As in ISIS-3, all patients were to receive aspirin unless contraindicated.
Methods
This multicentre European Study of the Prevention of Reocclusion after Initial Thrombolysis (ESPRIT) was conducted in Czechoslovakia, Estonia, France, Germany, Hungary, Italy, Norway, the Republic of Ireland and the United Kingdom (see Appendix A and Table 1 ). The study design was open and non-controlled. Its stated objectives were to measure the efficacy of a standard regimen of duteplase together with intravenous heparin and oral aspirin in acute myocardial infarction by recording rates of arteriographic patency and reocclusion of the infarct-related coronary artery, and to assess the safety thereof.
The protocol and consent form were approved by an independent Ethics Committee at each participating hospital and consent obtained, after detailed explanation of the nature of the study and procedures involved, from each patient. ESPRIT was funded by The Wellcome Foundation Ltd, who also manufactured and supplied the test drug duteplase.
Patient population
Patients were required to satisfy the following inclusion criteria: (1) age ^75 years, and women should not be of childbearing potential; (2) chest pain lasting ;>30min, which on clinical grounds was suspected to be due to acute myocardial infarction and was not immediately relieved by nitrate or nifedipine therapy, with onset <4 h before the time when duteplase infusion could be started; (3) ST-segment elevation on the electrocardiogram which, at 0-04 s after the J-point, was ;>01 mV in at least two of the leads reflecting one zone of infarction.
Patients were excluded from the study for the following reasons: (1) history of stroke or subarachnoid haemorrhage; (2) currently on oral anticoagulant therapy; (3) percutaneous transluminal coronary angioplasty procedure within the last 3 months, or previous coronary artery bypass graft or internal mammary artery implantation surgery at any time; (4) prosthetic heart valve; (5) dilated cardiomyopathy; (6) history of gastrointestinal bleeding within the last 12 months; (7) symptoms suggestive of, or proven, peptic ulcer disease within the last 6 months -unless on effective treatment; (8) surgical operation or trauma within the last 2 weeks; (9) blood pressure ^200mmHg systolic or S:120mmHg diastolic, by several measurements; (10) any medical condition for which bleeding could constitute a major hazard or present particular problems of management, and this included patients who had been subject to resuscitation with closed chest cardiac compression and in whom rib fracture or other trauma was suspected; (11) puncture of deeply located artery or vein within the last 2 weeks; (12) diagnosis of acute myocardial infarction impossible from the electrocardiogram; (13) time of onset of chest pain uncertain; (14) informed consent not obtained; (15) currently taking or within last 2 weeks had received another investigational drug; (16) previous administration of duteplase during present hospital admission.
Patient management
Duteplase (batch ct-PA 18) was administered intravenously as a 'lytic' infusion of 0-40 MU . kg" ' in the first hour, with 10% injected as a bolus in the first 60 s.
A 'maintenance' intravenous infusion of duteplase 0-20 MU . kg~' was then given over the next 3 h. Patients who weighed <50 kg were to receive the dose calculated for a 50 kg person and patients weighing >95 kg were to receive the dose calculated for a 100 kg person.
Heparin was administered as an intravenous bolus of 5000 IU prior to the start of duteplase infusion and further heparin administered as an intravenous infusion commencing 120 min after the start of the lytic infusion of duteplase and continuing for 48 h so as to maintain the activated partial thromoplastin time in the range of 1-5 to 20 times normal (for the local laboratory). Unless contraindicated, each patient also received soluble aspirin 300 mg orally at the beginning of the duteplase infusion and thereafter 300 mg orally each day for at least the duration of the study. A study period of 72 h was pre-defined.
Apart from the administration of duteplase and specified standard scheme of treatment with heparin and aspirin, patients were managed according to routine local coronary care practice. If, at the 90-min coronary arteriogram, the infarct-related coronary artery exhibited a high-grade stenosis and minimal perfusion (TIMI grade 0 or 1) associated with continuing chest pain, then the investigator was to proceed with any measures such as percutaneous transluminal coronary angioplasty or intracoronary administration of streptokinase which were considered necessary. The infusion of duteplase was to be stopped before intracoronary thrombolytic was given. After completion of the duteplase infusion the decision to perform any revascularization procedure was left to the discretion of the physician.
Coronary arteriography and assessment of arteriograms
Patients were taken to a cardiac catheterization laboratory for selective coronary arteriograms to be filmed at 90 min (permitted range 90-100 min) after the start of duteplase infusion. Where feasible, 60 min (permitted range 60-70 min) arteriograms were also filmed. Guidelines were provided to help investigators obtain adequate visualization of the general coronary arterial anatomy and the extent of atherosclerotic disease, and to secure the optimal view of the infarctrelated coronary artery with visualization of the infarctrelated coronary artery (including the distal part of the artery) from the time of injection of contrast until its clearance fro the distal arterial segment.
Patients with patent infarct-related coronary arteries, that is with perfusion grades of 2 or 3 (see next section for definitions) in the judgement of the local investigator, on the 90-min arteriograms were taken back to the catheterization laboratory for repeat coronary arteriography at 24 h (permitted range 20-36 h) after starting duteplase treatment. Consistency of procedure for all three sets of arteriograms was required so that, for example, if an intracoronary vasodilator was given for the 60-min arteriograms it should also have been given for the 90-min and 24-h arteriograms. Having determined the best view of the infarct-related coronary artery in the first set of arteriograms to be filmed, the same projection was to be used for filming at the later time-points.
All coronary arteriograms were subsequently forwarded to an independent core laboratory ( . In this scheme the extent of perfusion of the infarct-related coronary artery is graded as 0, 1, 2 or 3. Grade 0 is no perfusion, that is complete obstruction; Grade 1 is minimal perfusion across the zone of coronary arterial obstruction; Grade 2 is partial perfusion; Grade 3 is complete and unobstructed perfusion. The infarct-related coronary artery was identified at the core laboratory with the help of a copy of the 12-lead electrocardiogram recorded at entry to the study. The arteriograms were reviewed at the core laboratory by two cardiologists, who sought agreement on the identity of the infarct-related coronary artery and on the perfusion-related features before assigning the perfusion grade. If the assigned perfusion grade differed from that originally judged by the investigator the films were reviewed again by the core laboratory cardiologists before a final decision on the grade was made. It is the core laboratory perfusion grades which are presented in this report.
Reinfarction
Episodes of reinfarction during the study period of 72 h were recorded. The Investigator's diagnosis of reinfarction was accepted and no pre-specified criteria for making the diagnosis were issued.
Statistical analysis
The primary efficacy end-point of the study was the infarct-related coronary artery perfusion status, as judged by TIMI perfusion grade, at 90 min and it was calculated that in order to estimate patency (TIMI perfusion grades 2 or 3) of between 65% and 75% with an error of <10% a total sample size of >250 patients would be required. Secondary efficacy end-points were: (a) the infarct-related coronary artery perfusion status at 60 min, if it was possible to obtain arteriograms at that time; (b) in patients with a patent infarct-related coronary artery at 90 min, the infarct-related coronary artery perfusion status at 24 h (from which a reocclusion figure would be calculated); (c) reinfarction during the study period. Measures of safety were: (i) bleeding episodes and other adverse experiences, with 'serious or life-threatening bleeding' defined as bleeding from any site severe enough to require transfusion or surgical intervention, or bleeding significantly affecting clinical status, or intracranial or intrapericardial bleeding; (ii) death at any time prior to discharge from hospital.
The infarct-related coronary artery patency and reocclusion figures are expressed as means (with confidence intervals for some key results), and medians are also given. Other data are expressed as totals, means and medians, as appropriate.
Results
Enrolment of patients in the study lasted from June 1988 to July 1989, and 18 clinical centres participated. The senior investigators at these centres are listed in Appendix A. Table 1 lists the number of patients enrolled at each centre, grouped by countries, with an indication of whether or not inclusion criteria were met at enrolment. A total of 273 patients were enrolled in ESPRIT and their characteristics are presented in Table 2 . The median age of the patients was 59 years and 82% were men. The site of infarction was anterior in 52%, inferior in 47%, posterior in 1% and indeterminate in <1%.
The status of the enrolled patients at various points in the study is presented in Fig. 1 in a flow-chart form. For the efficacy analysis, 251 of the 273 enrolled patients had usable coronary arteriograms, and these included three 'incorrectly' enrolled patients (one with chest pain which had lasted 5 h 15 min before the duteplase infusion was started, one with an age of 76 years and one with no ST-segment elevation on the screening electrocardiogram). All of the 273 enrolled patients were included in the safety analysis.
The core laboratory coronary arteriographic analysis results are presented in detail in Tables 3 and 4 . The primary efficacy end-point of infarct-related coronary artery patency (TIMI perfusion grade 2 or 3) at 90 min yielded a result of 175/251 or 70% (95% CI 64-3%, 75-7%). With respect to the secondary efficacy end-points, infarct-related coronary artery patency (TIMI perfusion grade 2 or 3) at 60 min proved to be 163/251 or 65% (95% CI 591%, 70-9%) and reocclusion at 24 h of arteries patent at 90 min proved to be 11/165 or 7% (Table 4 ). The number of patients with TIMI grade 3 infarct-related coronary artery perfusion was 83/251 or 33% (95% CI 27-2%, 38-9%) at 60 min and 102/251 or 41% (95% CI 34-6%, 46-7%) at 90 min.
Reinfarction during the 72-h study period was reported in a total of 18/273 patients or 7%. The numbers of patients with evidence of reinfarction during this time is shown in Table 5 , subdivided according to the TIMI perfusion grade at 90 min.
In the safety analysis bleeding complications received principal attention (Table 6 ). There were 12/273, or 4%, serious or life-threatening and 1/273, or <1%, fatal bleeding complications; the fatal complication was a clinically diagnosed central nervous system haemorrhage in a previously hypertensive 68-year-old man, with death occurring within 4 h of the start of infusion of duteplase. The predominant serious or life-threatening bleeding complication was that of haematoma formation or bleeding at the vascular access site for the cardiac catheterization procedure, as expected. The absolute number of bleeding events was small, but there is a suggestion from these data that women are more susceptible to bleeding complications. Hospital deaths in the study totalled 21/273, or 8%. Data on the patients who died, including the hospital day of death (derived from calendar date) and cause of death, are presented in Table 7 . Most of the Eur Heart J, Vol. 17, October 1996 The ESPRIT Study 1527 patients who died had a cause of death which was either directly stated as acute myocardial infarction or stated in terms of a cardiological event, such as congestive heart failure or arrhythmia, which would be a common event in the context of acute myocardial infarction. There was only one death attributed to bleeding complications -a clinically diagnosed central nervous system haemorrhage, as mentioned earlier in this section. The 'Peri-operative' deaths occurred in a 55-yearold woman who died during cardiac catheterization with a left main coronary artery dissection at the time of the 60-min study arteriogram and in a 59-year-old man who died on Day 7 in hospital with a peri-operative myocardial infarction in relation to coronary artery bypass graft surgery.
Discussion
ESPRIT has confirmed the efficacy of duteplase in restoring antegrade flow in the infarct-related coronary artery in acute myocardial infarction. The 90-min patency figure for TIMI 2 or 3 perfusion grade in the were used. Two earlier trials of duteplase in acute myocardial infarction with duteplase regimens slightly different to the ESPRIT regimen had indicated similar 90-min patency rates [9?l0] . A further study with duteplase in acute myocardial infarction, contemporaneous with ESPRIT and conducted in the United States, used the same thrombolytic and heparin regimen as ESPRIT but without aspirin' 18 '; the 90-min infarct-related coronary artery patency figure among 470 patients was 69%, remarkably close to that in ESPRIT. For full patency of the infarct-related coronary artery, judged by a TIMI perfusion grade of 3, the 90-min patency figure in ESPRIT was 41% and in the contemporaneous duteplase study 1 ' 81 was 25%. The same independent core angiographic laboratory read the films for ESPRIT and for the study by Kalbfleisch et a/. [18] . Reperfusion in acute myocardial infarction offers the greatest benefit when it can be achieved soon after the onset of symptoms 1 ' 9 " 2 ' 1 and the 60-min patency figure for TIMI 2 or 3 perfusion grade in the infarctEur Heart J, Vol. 17, October 19% Table 4 The , but an alternative 'frontloaded' alteplase regimen was reported by Neuhaus et al. in 1989 1221 to yield an early patency rate of >80% without an apparent increase in bleeding risk. This regimen was subsequently evaluated in the rt-PA APSAC Patency Study (TAPS) and a 90-min infarctrelated coronary artery TIMI 2 or 3 perfusion grade of 84% was demonstrated in 199 patients' 231 . The same alteplase regimen was then used in one arm of the Global Utilization of Streptokinase and Tissue plasminogen activator for Occluded coronary arteries (GUSTO) study 1241 . In the GUSTO Angiographic Substudy a 90-min infarct-related coronary artery patency, with TIMI 2 or 3 perfusion grades, of 81% was achieved with the 'front-loaded' tissue-type plasminogen activator regimen in 292 patients treated within 6 h of onset of symptoms'
251
. This substudy provided evidence that the 'front-loaded' tissue-type plasminogen activator regimen was associated with a better clinical outcome than with streptokinase regimens which resulted in slower and less complete restoration of patency of infarct-related coronary arteries. The hypothesis of greater clinical benefit being secured with more rapid and complete restoration of coronary flow, whatever therapeutic agents are used to achieve this, was considerably strengthened by the GUSTO study'
211
. The 90-min infarct-related coronary artery patency figure has also gained greater credence as a worthwhile end-point.
It has been suggested' 261 that TIMI grade 2 patency is suboptimal and is associated with an increased risk of reocclusion and reinfarction and higher mortality compared to complete TIMI grade 3 patency. In ESPRIT there was a slightly higher 1-day reocclusion rate among patients with TIMI 2 vs TIMI 3 patency (6/70 or 9% vs 5/95 or 5%). However, among patients ; this difference was not significant. The disparate ESPRIT and GUSTO results in terms of the relationship between infarctrelated coronary artery early patency grade and later reocclusion with use of tissue-type plasminogen activator are derived from numbers in both studies which are too small to draw firm conclusions.
It is possible for patency of an occluded infarctrelated coronary artery to be re-established after 90 min and there is evidence that late reperfusion (up to 24 h after onset of symptoms) can prevent infarct expansion and ventricular remodelling, produce better electrical stability, and improve left ventricular ejection fraction and long-term prognosis' 27 " 291 . However, ESPRIT did not address the issue of whether later reopening of the infarct-related coronary artery, beyond 90 min postduteplase, may have procured any useful myocardial salvage.
In a pooled analysis of randomized acute myocardial infarction studies with alteplase the infarctrelated coronary artery reocclusion rate has been quoted as 13-5%, with a 95% CI of 11 to 16% (21 . In the duteplase study of Kalbfleisch et a/. Bleeding complications present the major clinical difficulty in the context of thrombolysis' 2 ''. Serious bleeding at 4% in ESPRIT is similar to that in the 'front-loaded' tissue-type plasminogen activator limb of the GUSTO study, in which puncture-site bleeding requiring transfusion was 4-3% [251 . In the TIMI-IIA trial the initial higher dose of tissue-type plasminogen activator had to be reduced because of haemorrhagic strokes' 5 ' 61 . The similar mortality figures for duteplase and streptokinase in ISIS-3' 13 ' and for alteplase and streptokinase in G1SSI-2' 32 ' and The International Study 1331 were accompanied by a significantly higher stroke rate in the tissue-type plasminogen activator treated groups' 13 ' 341 ; subcutaneous heparin plus oral aspirin were given in these studies. In ESPRIT there was only one stroke, which was haemorrhagic; in ISIS-3 the stroke rate in the duteplase subgroup was 1 -4% for any stroke and 07% for definitely or probably haemorrhagic stroke. The . However, no conclusions should be drawn concerning the effect of duteplase on mortality in acute myocardial infarction from a study such as ESPRIT in which only a few hundred patients were entered.
The major limitations of this exploratory study are its relatively small size, observational nature and the lack of a randomized control group. The reporting of patency figures with confidence intervals, does, however, provide an indication of the reliability of the observations, taking account of the number of patients evaluated. For ethical reasons we did not postpone the first duteplase bolus injection until an initial coronary arteriogram had been filmed and therefore, as in other contemporary studies of thrombolysis in acute myocardial infarction, we have no data on infarct-related coronary artery patency before thrombolysis.
Conclusions
Duteplase administered intravenously according to a weight-adjusted dosing scheme is both efficacious, as judged by patency of the infarct-related coronary artery, and safe in the management of acute myocardial infarction. Reocclusion of the infarct-related coronary artery did occur, although in less than 10% of patients, and reinfarction was also a problem. Serious haemorrhagic complications were infrequent.
